Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Development & Commercialization, Inc.
With
IQVIA Pty Ltd
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Primary Diagnostic and Statistical Manual of Mental Disorders (DSM), Fifth Edition criteria Diagnosis of Major Depressive Disorder, post-traumatic stress disorder, generalized anxiety disorder, panic disorder, social anxiety disorder or obsessive-compulsive disorder
Must be able to receive a sertraline dose of 150 mg/day by the second screening visit (Day -15)
You may not be if
Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days at the end of the study
Diagnosed hypertension (including treated or untreated hypertension), or orthostatic hypotension
Epilepsy or a history of seizures
History of neuroleptic malignant syndrome or serotonin syndrome.
Primary DSM-5 diagnosis of Schizophrenia spectrum and other psychotic disorders, Bipolar and related disorders, Feeding and eating disorders (including anorexia nervosa or bulimia), Neurocognitive disorders (including but not limited to delirium, major or mild neurocognitive disorder due to Alzheimer's, Parkinson's, or traumatic brain injury)
A significant risk of committing violent acts, serious self-harm, or suicide
History of diabetes mellitus (type 1 or type 2)
Subjects with any previous exposure to brexpiprazole, or subjects with chronic use of prazosin or propranolol in the 90 days prior to the screening visit or any use in the 21 days (3 weeks) prior to the screening visit.
Clareo Health | A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
